| Autor: |
Moy, Ryan H., Walch, Henry S., Mattar, Marissa, Chatila, Walid K., Molena, Daniela, Strong, Vivian E., Tang, Laura H., Maron, Steven B., Coit, Daniel G., Jones, David R., Hechtman, Jaclyn F., Solit, David B., Schultz, Nikolaus, de Stanchina, Elisa, Janjigian, Yelena Y. |
| Předmět: |
|
| Zdroj: |
JCO Precision Oncology; 2/9/2022, Vol. 6, p1-12, 12p |
| Abstrakt: |
Select patients had multiple PDX tumor samples harvested for PDX generation, and patients were considered in the success cohort if any PDX attempt resulted in successful engraftment. Of note, PDX engraftment is highly variable by tumor type, with some cancers such as colorectal cancer showing engraftment rates of over 89%,[36] whereas breast cancer PDXs have a lower take rate of 10%-25%.[37] The lower engraftment rate for EG PDXs is likely related to tumor-intrinsic factors. Notably, 88 patients (39%) had HER2-positive tumors, as many PDXs were generated from patients on clinical studies testing HER2-directed therapies. Importantly, genomic alterations found in patient tumor sequencing by clinical MSK-IMPACT were highly concordant with those identified by PDX sequencing: 234 mutation events observed in the clinical samples were also identified in the PDXs (58%), with 76 driver mutations in the clinical samples also being identified in the PDXs (60%). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
